May 02, 2012, 07.05 PM | Source: CNBC-TV18
D D Sharma of Risk Capital Advisors is of the view that one should buy Biocon.
Sharma told CNBC-Awaaz, "One can accumulate Biocon with a stoploss of Rs 229. The stock can touch level of Rs 255 in medium term."
The company touched its 52-week high Rs 382.00 and 52-week low Rs 225.75 on 20 Jul, 2011 and 27 Apr, 2012, respectively.
Currently, it is trading -37.72% below its 52-week high and 5.38% above its 52-week low.
Ashwani Gujral of ashwanigujral.com suggests buyin
Biocon shares touched a record high of Rs 1,049.50
The proposed biosimilar trastuzumab is one of the
Following US president-elect Donald Trump’s expl
Bengaluru-based biopharmaceutical firm Biocon on W